JP2013503894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503894A5 JP2013503894A5 JP2012528054A JP2012528054A JP2013503894A5 JP 2013503894 A5 JP2013503894 A5 JP 2013503894A5 JP 2012528054 A JP2012528054 A JP 2012528054A JP 2012528054 A JP2012528054 A JP 2012528054A JP 2013503894 A5 JP2013503894 A5 JP 2013503894A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 58
- 150000003839 salts Chemical class 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 9
- 229910052805 deuterium Inorganic materials 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 208000020832 chronic kidney disease Diseases 0.000 claims description 5
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 208000017667 Chronic Disease Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010022562 Intermittent claudication Diseases 0.000 claims description 3
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 200000000007 Arterial disease Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 206010019663 Hepatic failure Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 201000001431 Hyperuricemia Diseases 0.000 claims description 2
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 206010067362 Radiation necrosis Diseases 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 201000007527 Retinal artery occlusion Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 claims description 2
- 206010043391 Thalassaemia beta Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 208000026723 Urinary tract disease Diseases 0.000 claims description 2
- 208000012931 Urologic disease Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 208000012998 acute renal failure Diseases 0.000 claims description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000010227 enterocolitis Diseases 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims description 2
- 231100000268 induced nephrotoxicity Toxicity 0.000 claims description 2
- 230000000155 isotopic effect Effects 0.000 claims description 2
- 208000007903 liver failure Diseases 0.000 claims description 2
- 231100000835 liver failure Toxicity 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 201000005665 thrombophilia Diseases 0.000 claims description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
- 208000014001 urinary system disease Diseases 0.000 claims description 2
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 150000002431 hydrogen Chemical class 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 2
- 229960001476 pentoxifylline Drugs 0.000 description 2
- 0 *C(*)(CCCN(C(c1c(N2*)nc[n]1*)=O)C2=O)C(*)(*)O Chemical compound *C(*)(CCCN(C(c1c(N2*)nc[n]1*)=O)C2=O)C(*)(*)O 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23934209P | 2009-09-02 | 2009-09-02 | |
| US61/239,342 | 2009-09-02 | ||
| US12/873,991 US20110053961A1 (en) | 2009-02-27 | 2010-09-01 | Substituted xanthine derivatives |
| US12/873,991 | 2010-09-01 | ||
| PCT/US2010/047708 WO2011028922A1 (en) | 2009-09-02 | 2010-09-02 | Substituted xanthine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013503894A JP2013503894A (ja) | 2013-02-04 |
| JP2013503894A5 true JP2013503894A5 (OSRAM) | 2013-04-25 |
| JP5292516B2 JP5292516B2 (ja) | 2013-09-18 |
Family
ID=43625765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528054A Active JP5292516B2 (ja) | 2009-09-02 | 2010-09-02 | 置換キサンチン誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20110053961A1 (OSRAM) |
| EP (2) | EP2963040A1 (OSRAM) |
| JP (1) | JP5292516B2 (OSRAM) |
| KR (1) | KR101591137B1 (OSRAM) |
| CN (2) | CN104478881A (OSRAM) |
| AU (1) | AU2010289465B2 (OSRAM) |
| BR (1) | BR112012008108B1 (OSRAM) |
| CA (1) | CA2771123C (OSRAM) |
| DK (1) | DK2473053T3 (OSRAM) |
| EA (1) | EA023809B1 (OSRAM) |
| ES (1) | ES2542401T3 (OSRAM) |
| HR (1) | HRP20150797T1 (OSRAM) |
| HU (1) | HUE026800T2 (OSRAM) |
| IN (1) | IN2012DN01641A (OSRAM) |
| ME (1) | ME02177B (OSRAM) |
| MX (1) | MX2012002705A (OSRAM) |
| PH (1) | PH12012500278A1 (OSRAM) |
| PL (1) | PL2473053T3 (OSRAM) |
| PT (1) | PT2473053E (OSRAM) |
| SI (1) | SI2473053T1 (OSRAM) |
| WO (1) | WO2011028922A1 (OSRAM) |
| ZA (1) | ZA201201295B (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010009300A (es) * | 2008-02-29 | 2010-11-05 | Concert Pharmaceuticals Inc | Derivados de xantina substituidos. |
| WO2010075086A2 (en) * | 2008-12-15 | 2010-07-01 | Auspex Pharmaceuticals, Inc. | Pyrrolidinone inhibitors of pde-4 |
| US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
| JP2013503883A (ja) * | 2009-09-02 | 2013-02-04 | コンサート ファーマシューティカルズ インコーポレイテッド | 置換キサンチン誘導体 |
| US9260432B2 (en) | 2009-09-02 | 2016-02-16 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
| US9074233B2 (en) | 2010-09-01 | 2015-07-07 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
| US9085788B2 (en) | 2010-09-01 | 2015-07-21 | Concert Pharmaceuticals, Inc. | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation |
| US20130324564A1 (en) * | 2010-09-01 | 2013-12-05 | Concert Pharmaceuticals, Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)-dione |
| IN2014DN08443A (OSRAM) | 2012-04-13 | 2015-05-08 | Concert Pharmaceuticals Inc | |
| WO2013159006A1 (en) * | 2012-04-20 | 2013-10-24 | Concert Pharmaceuticals, Inc. | Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione |
| CA2981791A1 (en) * | 2014-04-18 | 2015-10-22 | Concert Pharmaceuticals, Inc. | Methods of treating hyperglycemia |
| WO2015175008A1 (en) * | 2014-05-14 | 2015-11-19 | Concert Pharmaceuticals, Inc. | Methods of treating chronic kidney disease characterized by macroalbuminuria |
| WO2015184248A1 (en) * | 2014-05-30 | 2015-12-03 | Concert Pharmaceuticals, Inc. | Methods of treating fibrotic diseases |
| JP6527948B2 (ja) * | 2014-10-09 | 2019-06-12 | クワントン レイノベント バイオテック カンパニー リミテッド | ヒドロキシプリン化合物及びその応用（ｈｙｄｒｏｘｙｌ ｐｕｒｉｎｅ ｃｏｍｐｏｕｎｄｓ ａｎｄ ａｐｐｌｉｃａｔｉｏｎｓ ｔｈｅｒｅｏｆ） |
| CN105566324B (zh) * | 2014-10-09 | 2020-04-03 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
| RU2685417C1 (ru) * | 2015-05-20 | 2019-04-18 | Гуандун Рейновент Биотек Ко., Лтд. | Гидроксипуриновые соединения и их применение |
| WO2017079003A1 (en) * | 2015-11-03 | 2017-05-11 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating blood cancers, and compositions and methods thereof |
| WO2017087207A1 (en) * | 2015-11-16 | 2017-05-26 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating hematologic malignant, inflammatory and autoimmune diseases |
| WO2021062089A1 (en) * | 2019-09-25 | 2021-04-01 | Goldfinch Bio, Inc. | Xanthine cb1 inhibitors |
| CN111440041B (zh) * | 2020-05-19 | 2021-03-05 | 北京理工大学 | 一种甲苯-d8的合成方法 |
| CN114380829A (zh) * | 2021-12-28 | 2022-04-22 | 赤峰万泽药业股份有限公司 | 一种己酮可可碱及其合成方法和应用 |
| WO2024199096A1 (zh) * | 2023-03-24 | 2024-10-03 | 陕西麦科奥特科技有限公司 | 一种抗凝逆转剂及其制备方法和应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE793059A (fr) | 1972-02-28 | 1973-04-16 | Ritzerfeld Gerhard | Dispositif d'encrage pour presses rotatives a |
| JPS5632477B2 (OSRAM) | 1973-03-07 | 1981-07-28 | ||
| DE2330742C2 (de) | 1973-06-16 | 1982-07-29 | Hoechst Ag, 6000 Frankfurt | 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| JPS5610188B2 (OSRAM) | 1973-09-14 | 1981-03-06 | ||
| JPS5756481B2 (OSRAM) | 1974-06-13 | 1982-11-30 | ||
| CA1037234A (en) | 1976-06-01 | 1978-08-29 | Aluma Building Systems Incorporated | Wall forming structure for poured concrete walls |
| FR2376188A1 (fr) | 1976-12-28 | 1978-07-28 | Elf Union | Procede de preparation de compositions de bitumes polymeres |
| JPS54120627A (en) | 1978-03-13 | 1979-09-19 | Nittetsu Kakoki Kk | Regenaration of asphalt concrete |
| JPS5576876A (en) | 1978-12-05 | 1980-06-10 | Grelan Pharmaceut Co Ltd | Preparation of 1-(oxoalkyl)-3,7-dimethylxanthine derivatne |
| JPS5581055A (en) | 1978-12-12 | 1980-06-18 | Kubota Ltd | Drawing device of pipe |
| JPS55122779A (en) | 1979-03-13 | 1980-09-20 | Maruko Seiyaku Kk | Preparation of theobromine derivative |
| CS201558B1 (en) | 1979-05-14 | 1980-11-28 | Pavol Kovar | Method of preparing 1-/5-oxohexyl/-3,7-dimethylxanthine |
| JPS5677279A (en) | 1979-11-28 | 1981-06-25 | Ota Seiyaku Kk | Preparation of xanthine derivative |
| JPS56125451A (en) | 1980-03-08 | 1981-10-01 | Mitsubishi Gas Chem Co Inc | Production of modified asphalt |
| JPS5762278A (en) | 1980-10-01 | 1982-04-15 | Sagami Chem Res Center | Theobromine derivative and its preparation |
| JPS5780385A (en) | 1980-11-05 | 1982-05-19 | Mitsubishi Petrochem Co Ltd | Preparation of 1-((omega-1)-oxoalkyl)-3,7-dialkylxanthine |
| JPS5785387A (en) | 1980-11-14 | 1982-05-28 | Teikoku Chem Ind Corp Ltd | Preparation of 1-(-5'-oxohexyl)-3,7-dimethylxanthine |
| JPS5798284A (en) | 1980-12-10 | 1982-06-18 | Kawashima Yakuhin Kaihatsu Kk | Preparation of 1-(5-oxohexyl)-3,7-dimethylxanthine |
| JPS5838284B2 (ja) | 1981-04-14 | 1983-08-22 | ミサワホ−ム株式会社 | 脱型装置 |
| JPS57200391A (en) | 1981-06-02 | 1982-12-08 | Daito Koeki Kk | 1-(5-oxo-2-hexenyl)3,7-dimethylxanthine |
| JPS58134092A (ja) | 1982-02-05 | 1983-08-10 | Sagami Chem Res Center | テオブロミン誘導体 |
| JPS58150594A (ja) | 1982-03-03 | 1983-09-07 | Daito Koeki Kk | キサンチン誘導体の製造方法 |
| CS237719B1 (cs) | 1983-05-12 | 1985-10-16 | Jan Jendrichovsky | SpAsob přípravy dimetyl-(5-oxohexyl)-xantlnov |
| DE3508097A1 (de) | 1984-07-21 | 1986-02-06 | Hoechst Ag, 6230 Frankfurt | Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung |
| DD274334A3 (de) | 1985-12-17 | 1989-12-20 | Dresden Arzneimittel | Verfahren zur herstellung von reinem 3,7-dimethyl-1-(5-oxohexyl)-xanthin |
| IL106859A (en) | 1986-12-31 | 1996-10-16 | Hoechst Roussel Pharma | Pentoxifilin metabolites and pharmaceutical preparations containing them for the treatment of VIH and similar diseases |
| CS263595B1 (sk) | 1988-01-06 | 1989-04-14 | Rybar Alfonz | Spdsob pripravy 7-n-prnpyl-3-metyl 3,7-dihydro-lH-purín-2,6-dionu |
| JP2661666B2 (ja) | 1988-02-19 | 1997-10-08 | ヘキスト薬品工業株式会社 | 抗消化性潰瘍剤 |
| IT1231779B (it) | 1989-08-09 | 1991-12-21 | Eniricerche Spa | Procedimento per l'ossidazione di composti paraffinici. |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| DE3942872A1 (de) | 1989-12-23 | 1991-06-27 | Hoechst Ag | Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen |
| US5112827A (en) * | 1990-05-18 | 1992-05-12 | Board Of Regents, The University Of Texas System | Drug to reverse fatty liver and atheromatous lesions |
| WO1992007566A2 (en) | 1990-11-01 | 1992-05-14 | Board Of Regents, The University Of Texas System | Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues |
| ATE138266T1 (de) | 1990-11-07 | 1996-06-15 | Hoechst Roussel Pharma | Verwendung von xanthinen zur herstellung von arzneimitteln zur hemmung der vermehrung menschlicher retroviren |
| EP0490181A1 (en) | 1990-11-30 | 1992-06-17 | Hoechst-Roussel Pharmaceuticals Incorporated | Use of xanthines for preparation of a medicament having immunosuppressing activity |
| EP0493682A3 (en) | 1990-11-30 | 1992-11-19 | Hoechst-Roussel Pharmaceuticals Incorporated | Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans |
| US5763446A (en) | 1992-03-26 | 1998-06-09 | University Of Southern California | Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases |
| US5780476A (en) * | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| HUT68560A (en) | 1993-08-02 | 1995-04-27 | Chinoin Gyogyszer Es Vegyeszet | The use of xantine derivatives for promotion of healing of operative lesions |
| CA2186371A1 (en) * | 1994-03-25 | 1995-10-05 | Robert T. Foster | Enhancement of the efficacy of dihydropyridines by deuteration |
| JPH10507156A (ja) | 1994-05-16 | 1998-07-14 | セル・セラピューティックス・インコーポレーテッド | キラル第二級アルコールの不斉合成 |
| WO1996005836A2 (en) | 1994-08-25 | 1996-02-29 | Medical University Of South Carolina | Methods of treating cold symptoms using pentoxifylline |
| DE4430128A1 (de) | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE19544768C1 (de) | 1995-11-30 | 1997-07-10 | Rentschler Arzneimittel | Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose |
| US5985592A (en) | 1997-06-05 | 1999-11-16 | Dalhousie University | Uses for pentoxifylline or functional derivatives/metabolites thereof |
| US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| US6248889B1 (en) | 1998-11-20 | 2001-06-19 | 3M Innovative Properties Company | Process for converting an alcohol to the corresponding fluoride |
| US6417208B1 (en) | 1999-02-05 | 2002-07-09 | Albert Einstein College Of Medicine Of Yeshiva University | Method of identification of inhibitors of PDE1C |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| GB0102107D0 (en) | 2001-01-26 | 2001-03-14 | Syngenta Ltd | Chemical process |
| BR0209325A (pt) | 2001-05-03 | 2004-07-20 | Hoffmann La Roche | Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo |
| EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| WO2003013568A1 (en) | 2001-08-02 | 2003-02-20 | Ortho-Mcneil Pharmaceutical, Inc. | Cytokine modulation therapy |
| WO2003037432A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| WO2003077949A2 (en) | 2002-03-14 | 2003-09-25 | Bayer Pharmaceuticals Corporation | Methods of treating diabetes using pde 11a inhibitors |
| DE10214228A1 (de) | 2002-03-22 | 2003-10-02 | Bdd Group Holding Ag Zug | Deuterierte substitutierte Indole sowie diese Verbindungen enthaltende Arzneimittel |
| US20050107420A1 (en) * | 2002-05-23 | 2005-05-19 | Boehringe Ingelheim Pharma Gmbh & Co. Kg | Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| CA2530316A1 (en) | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolodihydroisoquinolines as pde10 inhibitors |
| US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| WO2005023193A2 (en) | 2003-09-04 | 2005-03-17 | Interleukin Genetics, Inc. | Methods of treating endometriosis |
| JP2008501776A (ja) | 2004-06-07 | 2008-01-24 | ファイザー・プロダクツ・インク | 肥満に関連し、かつメタボリックシンドロームに関連する状態の治療としてのホスホジエステラーゼ１０の阻害 |
| WO2006035418A2 (en) | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Microcapsules comprising a methylxanthine and a corticosteroid |
| CA2581169A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| CN101309917B (zh) | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| MX2010009300A (es) * | 2008-02-29 | 2010-11-05 | Concert Pharmaceuticals Inc | Derivados de xantina substituidos. |
-
2010
- 2010-09-01 US US12/873,991 patent/US20110053961A1/en not_active Abandoned
- 2010-09-02 ME MEP-2015-108A patent/ME02177B/me unknown
- 2010-09-02 PL PL10814504T patent/PL2473053T3/pl unknown
- 2010-09-02 DK DK10814504.6T patent/DK2473053T3/en active
- 2010-09-02 EP EP15163741.0A patent/EP2963040A1/en not_active Withdrawn
- 2010-09-02 PT PT108145046T patent/PT2473053E/pt unknown
- 2010-09-02 EA EA201270339A patent/EA023809B1/ru not_active IP Right Cessation
- 2010-09-02 HU HUE10814504A patent/HUE026800T2/en unknown
- 2010-09-02 EP EP20100814504 patent/EP2473053B1/en active Active
- 2010-09-02 PH PH1/2012/500278A patent/PH12012500278A1/en unknown
- 2010-09-02 SI SI201030985T patent/SI2473053T1/sl unknown
- 2010-09-02 BR BR112012008108A patent/BR112012008108B1/pt active IP Right Grant
- 2010-09-02 CN CN201410746544.2A patent/CN104478881A/zh active Pending
- 2010-09-02 CA CA2771123A patent/CA2771123C/en active Active
- 2010-09-02 ES ES10814504.6T patent/ES2542401T3/es active Active
- 2010-09-02 AU AU2010289465A patent/AU2010289465B2/en active Active
- 2010-09-02 CN CN201080039090.5A patent/CN102480968B/zh active Active
- 2010-09-02 HR HRP20150797TT patent/HRP20150797T1/hr unknown
- 2010-09-02 JP JP2012528054A patent/JP5292516B2/ja active Active
- 2010-09-02 MX MX2012002705A patent/MX2012002705A/es active IP Right Grant
- 2010-09-02 IN IN1641DEN2012 patent/IN2012DN01641A/en unknown
- 2010-09-02 WO PCT/US2010/047708 patent/WO2011028922A1/en not_active Ceased
- 2010-09-02 KR KR1020127008446A patent/KR101591137B1/ko active Active
-
2012
- 2012-02-21 ZA ZA2012/01295A patent/ZA201201295B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013503894A5 (OSRAM) | ||
| JP2013503883A5 (OSRAM) | ||
| JP2011513307A5 (OSRAM) | ||
| JP2011513309A5 (OSRAM) | ||
| JP4638491B2 (ja) | シナカルセト塩酸塩結晶フォームｉの調製方法 | |
| JP2008513358A5 (OSRAM) | ||
| JP2013500986A5 (OSRAM) | ||
| JP2008518890A5 (OSRAM) | ||
| JP2019052152A (ja) | トレプロスチニルの塩 | |
| JP2015512947A5 (OSRAM) | ||
| JP2008507566A6 (ja) | シナカルセト塩酸塩結晶フォームｉの調製方法 | |
| RU2009137124A (ru) | Соединения, активные в отношении ppar | |
| CA2607848A1 (en) | 3-substituted (3-phenyl)-propionic acid derivatives for the treatment of metabolic disorders | |
| JP2013526494A5 (OSRAM) | ||
| JP2009543795A5 (OSRAM) | ||
| JP2009528275A5 (OSRAM) | ||
| JP2025513554A (ja) | Ｈｐｋ１キナーゼ阻害剤のヒトの病原体感染の予防及び／又は治療への応用 | |
| TW201043226A (en) | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof | |
| JP5734952B2 (ja) | 新規なｅｐ４アゴニスト | |
| WO2008061456A1 (en) | The folacin-metformin compound and its manufacture | |
| WO2011107903A1 (en) | Highly pure mosapride citrate dihydrate and processes for its preparation | |
| JP2009502777A5 (OSRAM) | ||
| CN103724339B (zh) | 二氢嘧啶衍生物的晶型 | |
| KR20130083592A (ko) | 치환된 피페리딘 유도체 및 이의 제조방법 | |
| CN104672210B (zh) | 阿格列汀和苯甲酸阿格列汀的制备方法 |